Compare AOSL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | ARVN |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.9M | 781.0M |
| IPO Year | 2010 | 2018 |
| Metric | AOSL | ARVN |
|---|---|---|
| Price | $20.96 | $12.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 23 |
| Target Price | ★ $23.67 | $18.14 |
| AVG Volume (30 Days) | 423.5K | ★ 752.6K |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $685,883,000.00 | $312,300,000.00 |
| Revenue This Year | N/A | $10.55 |
| Revenue Next Year | $6.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.92 | ★ 93.86 |
| 52 Week Low | $15.90 | $5.90 |
| 52 Week High | $42.00 | $20.38 |
| Indicator | AOSL | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 49.75 |
| Support Level | $20.04 | $12.90 |
| Resistance Level | $23.39 | $14.00 |
| Average True Range (ATR) | 1.46 | 0.70 |
| MACD | -0.25 | -0.05 |
| Stochastic Oscillator | 58.62 | 20.73 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.